DAYANG BIOTECH(003017)2025-04-21 11:45Financial Performance - The company's revenue for Q1 2025 was CNY 248,970,295.20, representing a 27.78% increase compared to CNY 194,843,722.18 in the same period last year[5] - Net profit attributable to shareholders was CNY 29,343,179.68, up 73.44% from CNY 16,918,222.12 year-on-year[5] - Basic earnings per share rose to CNY 0.3607, reflecting a 74.08% increase from CNY 0.2072 in the same quarter last year[5] - Operating profit for the current period was 17,891,627.59 in the previous period[18] - Net profit for the current period was 16,918,222.12 in the previous period[19] - Earnings per share (EPS) for the current period was 0.2072 in the previous period, reflecting a significant growth[19] Cash Flow - The net cash flow from operating activities surged to CNY 42,610,970.40, a remarkable increase of 24,070.81% compared to CNY 176,291.06 in the previous year[5] - Operating cash flow for the current period is ¥42,610,970.40, a significant increase from ¥176,291.06 in the previous period[20] - Total cash inflow from operating activities is ¥228,516,777.26, compared to ¥177,121,488.87 in the prior period, reflecting a growth of approximately 29%[20] - Cash outflow from operating activities is ¥185,905,806.86, slightly up from ¥176,945,197.81, resulting in a net cash flow from operating activities of ¥42,610,970.40[20] - Investment cash inflow is ¥68,539,082.22, a substantial increase from ¥692,864.50 in the previous period[20] - Net cash flow from investment activities is ¥4,468,256.98, recovering from a negative cash flow of -¥26,556,560.83 in the prior period[20] - Total cash inflow from financing activities is ¥71,940,000.00, down from ¥129,039,694.43 in the previous period[21] - Net cash flow from financing activities is -¥48,564,510.57, an improvement from -¥55,746,748.63 in the prior period[21] - The ending cash and cash equivalents balance is ¥346,190,068.30, compared to ¥299,853,950.19 at the end of the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,654,898,791.87, showing a slight increase of 0.08% from CNY 1,653,549,319.97 at the end of the previous year[5] - Total liabilities decreased to 600,399,526.09 in the previous period, indicating improved financial stability[17] - The total current assets amount to ¥695,529,906.75, slightly up from ¥690,549,046.95[15] Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,959[11] - The top 10 shareholders hold a combined 29.29% of the shares, with the largest shareholder, Chen Yanggui, owning 8.86%[11] - The company has no preferred shareholders or significant changes in the top 10 shareholders due to margin trading[13] - The company is actively involved in employee stock ownership plans, with significant holdings by key individuals[12] - There are no reported changes in the status of shares due to margin trading or lending activities among the top shareholders[13] Research and Development - The company reported a significant increase in research and development expenses, which reached CNY 8,948,093.95, a 35.06% rise from CNY 6,625,360.56 in the prior year[8] - Research and development expenses rose to 6,625,360.56, highlighting the company's commitment to innovation[18] Other Financial Metrics - The accounts receivable increased by 51.56% to CNY 89,047,616.80, primarily due to delayed payments from major clients[8] - The company experienced a 84.54% increase in notes payable, amounting to CNY 94,335,216.40, attributed to higher payment obligations for goods received[8] - The company recorded a significant increase in sales expenses, which amounted to CNY 2,744,277.15, a 57.79% increase compared to CNY 1,739,190.20 in the same period last year[8] - Inventory at the end of the reporting period is ¥120,182,793.46, showing a marginal increase from ¥119,784,613.63[15] - Long-term equity investments increased to ¥102,618,150.25 from ¥100,970,777.38, indicating a growth of 1.63%[15] - Unallocated profits increased to 413,769,491.63, showing a positive trend in retained earnings[17] Audit Status - The company has not audited the first quarter report for 2025[22]